Trial Profile
Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Dec 2023
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary) ; Tofacitinib
- Indications Axial spondyloarthritis
- Focus Therapeutic Use
- 16 Dec 2023 Planned End Date changed from 31 Mar 2024 to 30 Dec 2024.
- 16 Dec 2023 Planned primary completion date changed from 31 Mar 2024 to 30 Jun 2024.
- 08 Nov 2023 New trial record